Neues in der Schlaganfallprävention

D. Sander; K. Winbeck; T. Etgen; M. Landgrebe; B. Conrad

doi:10.1055/s-0038-1626307

Nervenheilkunde, Inhaltsverzeichnis

Nervenheilkunde 2003; 22(06): 295-300
DOI: 10.1055/s-0038-1626307

Original- und Übersichtsarbeiten/Original and Review Articlesxs

Schattauer GmbH

Neues in der Schlaganfallprävention

Moderne Differenzialtherapie mit ThrombozytenfunktionshemmernNew aspects of stroke preventionModern differential therapy with platelet inhibitors

Autoren

D. Sander

¹Neurologische Klinik der TU München (Direktor: Prof. Dr. med. Bastian)
K. Winbeck

¹Neurologische Klinik der TU München (Direktor: Prof. Dr. med. Bastian)
T. Etgen

¹Neurologische Klinik der TU München (Direktor: Prof. Dr. med. Bastian)
M. Landgrebe

¹Neurologische Klinik der TU München (Direktor: Prof. Dr. med. Bastian)
B. Conrad

¹Neurologische Klinik der TU München (Direktor: Prof. Dr. med. Bastian)

Abstract

Zusammenfassung

Der Schlaganfall ist die häufigste zu dauerhafter Behinderung führende Erkrankung. Neben der effektiven Diagnose und Therapie der Risikofaktoren im Rahmen der Primär-und Sekundärprävention kommt der Gabe von Thrombozytenfunktionshemmern (TFH) zur Sekundärprävention des Schlaganfalls eine wesentliche Bedeutung zu. Neben der Azetylsalizylsäure (ASS) stehen als weitere Substanzen Clopidogrel und die Kombination aus ASS und Dipyridamol zur Verfügung. In der folgenden Übersicht soll die Differenzialtherapie mit den unterschiedlichen Thrombozytenfunktionshemmern dargestellt werden. Ausführlicher wird dabei insbesondere auf mögliche Therapieoptionen bei komplexeren Konstellationen wie z. B. dem persistierenden offenen Foramen ovale oder intrakraniellen Stenosen eingegangen sowie mögliche Indikationen für eine Kombinationstherapie von ASS mit anderen TFH dargestellt.

Summary

In industrialized countries, stroke is a leading cause of death. Of those patients that survive a stroke, many will have to cope with long-term disability. In addition to the effective diagnosis and therapy of known cardiovascular risk factors for primary and secondary prevention strategies, platelet inhibitors are important for the secondary prevention of stroke. Apart from aspirin, the platelet inhibitors clopidogrel and the combination of aspirin and dipyridamole are available. In the following paper we present an overview on the current status of modern differential therapy with the different platelet inhibitors. Possible therapeutic strategies in more complex clinical constellations such as the persistent foramen ovale, intracranial stenosis were described in more detail and possible indications for the combined application of platelet inhibitors are discussed.

Schlüsselwörter

Hirninfarkt - Prävention - Thrombozytenfunktionshemmer - Differenzialtherapie

Keywords

Stroke - prevention - antiplatelet drugs - differential therapy

Volltext

Referenzen

Literatur
1 Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med 1996; 334 (19) 1216-21.
2 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324 (7329): 71-86.
3 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348 9038 1329-39.
4 A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997; 42 (06) 857-65.
5 Akins PT, Pilgram TK, Cross DT, Moran CJ. Natural history of stenosis from intracranial atherosclerosis by serial angiography. Stroke 1998; 29 (02) 433-8.
6 Albers GW, Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascular patients?. Stroke 2001; 32 (12) 2948-9.
7 Arenillas JF, Molina CA, Montaner J, Abilleira S, Gonzalez-Sanchez MA, Alvarez-Sabin J. Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a longterm follow-up transcranial Doppler ultrasound study. Stroke 2001; 32 (12) 2898-904.
8 Benesch CG, Chimowitz MI. Best treatment for intracranial arterial stenosis? 50 years of uncertainty. The WASID Investigators. Neurology 2000; 55 (04) 465-6.
9 Bhatt DL. et al. J Am Coll Cardiol. 2000; 35 (Suppl A): 326A 383A, 408A.
10 Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103 (03) 363-8.
11 Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345 (25) 1809-17.
12 Chimowitz MI. Angioplasty or stenting is not appropriate as first-line treatment of intracranial stenosis. Arch Neurol 2001; 58 (10) 1690-2.
13 Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, Pessin MS, Weichel E, Sila CA, Furlan AJ. et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995; 45 (08) 1488-93.
14 Dearani JA, Ugurlu BS, Danielson GK, Daly RC, McGregor CG, Mullany CJ, Puga FJ, Orszulak TA, Anderson BJ, Brown Jr RD, Schaff HV. Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events. Circulation 1999; 100 (Suppl. 19) II171-5.
15 Diener HC. Aspirin therapy should be first-line treatment in secondary prevention of stroke. Stroke 2002; 33 (08) 2138-9.
16 Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143 1-2 1-13.
17 Gorter JW, De Schryver EL, Algra A. [Secondary prevention after ischemic cerebral infarct. The ESPRIT Study: low dose anticoagulation, combined therapy with acetylsalicylic acid/ dipyridamole or monotherapy with acetylsalicylic acid?]. Nervenarzt 1999; 70 (04) 368-70.
18 Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105 (22) 2625-31.
19 Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345 (24) 1740-6.
20 Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams Jr HP, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345 (20) 1444-51.
21 Orgera MA, O’Malley PG, Taylor AJ. Secondary prevention of cerebral ischemia in patent foramen ovale: systematic review and metaanalysis. South Med J 2001; 94 (07) 699-703.
22 Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55 (08) 1172-9.
23 Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353 9171 2179-84.
24 Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology 2000; 55 (04) 490-7.
25 Warlow C. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. Stroke 2002; 33 (08) 2137-8.
26 Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992; 49 (08) 857-63.
27 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502.